Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 4Phase 3 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 58Breast Neoplasms 43Prostatic Neoplasms 32Lung Neoplasms 29Multiple Myeloma 23Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 17Ovarian Neoplasms 17Colorectal Neoplasms 17Neoplasm Metastasis 16Leukemia, Lymphocytic, Chronic, B-Cell 16Carcinoma, Renal Cell 14Pancreatic Neoplasms 13Endometrial Neoplasms 12Small Cell Lung Carcinoma 11Urinary Bladder Neoplasms 10Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Myasthenia Gravis 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Fallopian Tube Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Colonic Neoplasms 8Burkitt Lymphoma 7Recurrence 6Lymphoma, Mantle-Cell 6Esophageal Neoplasms 6Adenocarcinoma 6Triple Negative Breast Neoplasms 5

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Papillomavirus Infections × 30 days × Clear all
NCT07217145 2026-06-05

PREVENT HPV -Related Cancers Trial

University of Utah

Phase 3 Active not recruiting
1,455 enrolled

Behavior, Communication, Neoplasms, Patient Acceptance of Health Care, Papillomavirus Infections

NCT03998254 2026-06-02

V503-023

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
6,000 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡